Which patients with diabetes should be prescribed low‑dose aspirin (75–100 mg daily)?

Low-Dose Aspirin Therapy in Diabetes: Patient Selection

Low-dose aspirin (75–162 mg daily) should be prescribed to all patients with diabetes who have established atherosclerotic cardiovascular disease (ASCVD), while for primary prevention it may be considered only in those at increased cardiovascular risk after weighing bleeding hazards against modest benefits. 1

Secondary Prevention (Established ASCVD) – ALWAYS Prescribe

Aspirin is strongly indicated for all diabetic patients with a history of:

• Prior myocardial infarction, stroke, or transient ischemic attack 1
• Documented coronary artery disease or peripheral artery disease 1
• Any prior atherosclerotic cardiovascular event 1

Dosing: 75–162 mg daily, with preference for plain (non-enteric-coated) formulations at 75–100 mg to maximize bioavailability and platelet inhibition 2

Key point: This recommendation holds even with platelet counts ≥50 × 10³/µL, as the mortality benefit outweighs bleeding risk 2

Primary Prevention – Selective Use Only

Aspirin may be considered in diabetic patients WITHOUT established ASCVD who meet ALL of the following criteria: 1

Patient Selection Criteria:

• Age ≥50 years 1
• At least one additional major cardiovascular risk factor: 1
  • Family history of premature ASCVD
  • Hypertension
  • Dyslipidemia
  • Current smoking
  • Chronic kidney disease or albuminuria
• Low bleeding risk (absence of older age >70 years, anemia, advanced renal disease) 1
• Estimated ASCVD risk >1% per year 1

Special Consideration for Moderate Renal Dysfunction:

• Patients with estimated glomerular filtration rate (eGFR) 60–89 mL/min/1.73 m² may derive particular benefit from aspirin, showing significant reduction in atherosclerotic events (hazard ratio 0.57) 3
• No benefit demonstrated in those with eGFR ≥90 or <60 mL/min/1.73 m² 3

Who Should NOT Receive Aspirin for Primary Prevention

Avoid aspirin in diabetic patients with: 1

• Age >70 years – bleeding risk exceeds cardiovascular benefit 1
• Low baseline cardiovascular risk (<1% per year) 1
• Increased bleeding risk: history of gastrointestinal bleeding, peptic ulcer disease, concurrent anticoagulation, thrombocytopenia, or bleeding disorders 1
• No additional cardiovascular risk factors beyond diabetes alone 1

Evidence Nuances and Clinical Context

The ASCEND Trial Reality:

The landmark ASCEND trial in 15,480 diabetic patients without cardiovascular disease showed aspirin reduced serious vascular events by 12% (8.5% vs 9.6%), but increased major bleeding by 29% (4.1% vs 3.2%) over 7.4 years 4. The absolute benefits were largely counterbalanced by bleeding hazards – for every 1000 patients treated, aspirin prevents approximately 0.68 cardiovascular events but causes 1.49 additional bleeding episodes annually 5.

Risk Stratification Matters:

Meta-analysis data suggest that in moderate-to-high cardiovascular risk diabetic patients, aspirin reduces major adverse cardiovascular events (OR 0.88), whereas no significant benefit occurs in low-risk patients 6. However, bleeding risk increases across all risk strata 6.

Dosing Considerations:

• 30 mg daily is insufficient in diabetic patients, particularly those with poor glycemic control (HbA1c >53 mmol/mol), resulting in incomplete platelet suppression 7
• 100 mg daily achieves optimal platelet inhibition regardless of glycemic control 7
• 300 mg provides no additional benefit over 100 mg but increases gastrointestinal bleeding 2

Common Pitfalls to Avoid

Do not prescribe aspirin for primary prevention based solely on diabetes diagnosis – additional cardiovascular risk factors must be present 1

Do not continue aspirin in elderly diabetic patients (>70 years) for primary prevention – net harm exceeds benefit 1

Do not use enteric-coated formulations – reduced bioavailability may lead to inadequate antiplatelet effect 2

Do not withhold aspirin in secondary prevention due to mild thrombocytopenia (platelets ≥50 × 10³/µL) unless active bleeding or high-risk surgery is planned 2

Dual Antiplatelet Therapy

For diabetic patients with stable coronary or peripheral artery disease and low bleeding risk, combination therapy with aspirin plus low-dose rivaroxaban should be considered to prevent major adverse limb and cardiovascular events 1. The duration of dual antiplatelet therapy after acute coronary syndrome or stroke requires interprofessional team input including cardiovascular or neurological specialists 1.

Aspirin Allergy Alternative

For diabetic patients with documented aspirin allergy and established ASCVD, clopidogrel 75 mg daily should be substituted 1.